This will be a multi-center, prospective, randomized, single-blinded, placebo-controlled phase II trial of trastuzumab + nelipepimut-S/GM-CSF versus trastuzumab + GM-CSF alone. Our target study population is high-risk HER2-positive breast cancer patients. High-risk HER2-positive breast cancer patients are defined as:
Those with HER2-positive breast cancer, regardless of hormone receptor status, who receive neoadjuvant therapy with an approved regimen that includes trastuzumab and at least four cycles (12 weeks) of taxane-containing chemotherapy, and fail to achieve a pCR.
Those with HER2-positive breast cancer, regardless of hormone receptor status, who undergo surgery as a first intervention and are found to have ≥ 4 positive lymph nodes.
Those with HER2-positive, hormone receptor negative breast cancer who undergo surgery as a first intervention and are found to have 1-3 positive lymph nodes.
Disease-free subjects after standard of care multi-modality therapy will be screened and HLA-typed.

Start Date01 Oct 2014

Sponsor / Collaborator

LumaBridge LLCStartup

[+2]

NCT01570036 / CompletedPhase 2

Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence

The study will be a multi-center, prospective, randomized, single-blinded, placebo-controlled Phase II trial of Herceptin + NeuVax(TM) vaccine (E75 peptide/granulocyte macrophage-colony stimulating factor) (GM-CSF) versus Herceptin + GM-CSF alone. The target study population is node-positive (NP) (or node-negative [NN] if negative for both ER and PR) breast cancer patients with HER2 1+ and 2+ expressing tumors who are disease-free after standard of care therapy. Disease-free subjects after standard of care multi-modality therapy will be screened and HLA-typed. E75 is a CD8-eliciting peptide vaccine that was restricted to HLA-A2+ or HLA-A3+ patients (approximately two-thirds of the US population), and has been extended to HLA-A24+ and HLA-A26+ as well.

Start Date21 May 2013

Sponsor / Collaborator

LumaBridge LLCStartup

[+2]

NCT01479244 / CompletedPhase 3

PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment

Purpose of this trial:
To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF).
To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects.

Start Date01 Nov 2011

Sponsor / Collaborator

Galena Biopharma, Inc.

100 Clinical Results associated with Nelipepimut S

100 Translational Medicine associated with Nelipepimut S

100 Patents (Medical) associated with Nelipepimut S

840

Literatures (Medical) associated with Nelipepimut S

01 Dec 2024·SCIENCE OF THE TOTAL ENVIRONMENT

Application of oxide nanoparticles mitigates the salt-induced effects on photosynthesis and reduces salt injury in Cyclocarya paliurus

Article

Author: Fang, Jie ; Fang, Shengzuo ; Jin, Huiyin ; Zhang, Zijie ; Zhang, Lei

Salinization is very detrimental to photosynthetic processes and plant growth, while nanoparticles (NPs) are considered to be the emerging materials to improve plant adaptability to salt stress. Cyclocarya paliurus is being planted on saline-alkali soils to meet the growing demand for its leaves and medicinal products. However, this species exhibits low salt tolerance and little information is available on whether NPs application would mitigate the salt-induced effects. This study explored the influence of three oxide NPs and their application doses on improving salt tolerance in C. paliurus under simulated natural conditions. The results showed that these oxide NPs could modify the salt tolerance in C. paliurus seedlings, but the alleviating effects varied in the NPs types and their application doses. Under the salt stress, foliar applications of SiO₂-NPs with 500 mg L^-1 and MnO₂-NPs with 50 mg L^-1 significantly increased net photosynthetic rate and seedling height by 52.0-59.5 %, and reduced the salt injury index by 67.6-70.7 %. Transcriptomic analysis revealed that the genes related to photosynthesis pathway were well responsive to both salt stress and NPs application, while the applications of high-dose SiO₂- and MnO₂-NPs up-regulated the expression of 50 photosynthesis-related genes. Weighted gene co-expression network analysis (WGCNA) indicated there existed a close relationship between physiological parameters and gene expression patterns, and the nine key genes in mitigating salt stress in C. paliurus were identified after the NPs application. Our findings suggested that the effects of NPs on mitigating salt-induced damages depending on the NP type and applied dose. The applications of SiO₂-NPs and MnO₂-NPs with an appropriate dose hold great promise for mitigating the salt-induced photosynthetic dysfunction via regulation of related key genes, and ultimately promoting plant growth and ameliorating the salt-tolerance.

01 Dec 2024·NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Postmortem findings of organ damage in novel psychoactive substances users: A comprehensive review

Review

Author: Corkery, John M ; De-Giorgio, Fabio ; Bassi, Marta ; Bilel, Sabrine ; Corli, Giorgia ; Benedetti, Beatrice ; Corkery, John M. ; Conte, Celeste ; Di Santo, Riccardo ; Marti, Matteo ; Bergamin, Eva ; Ciasca, Gabriele ; Schifano, Fabrizio

INTRODUCTION:

Despite the rising number of NPS-related deaths, comprehensive data on their prevalence, identification, and associated organ damage remain scarce.

MATERIALS AND METHODS:

A literature search was conducted. Predefined inclusion and exclusion criteria were applied, resulting in the identification of 197 articles.

RESULTS:

We identified 446 cases of NPS-related deaths, involving a total of 176 different substances. Synthetic opioids were the most prevalent class (34 %), followed by synthetic cannabinoids (22 %) and cathinones (21 %). Co-ingestion of NPS with other substances occurred in 77 % of cases. Macroscopic findings varied across organs, with congestion and edema most observed in the brain (23 %) and lung (56 %), respectively.

DISCUSSION:

The existing literature lacks comprehensive descriptions of organs subjected to autopsy and histological examination in NPS-positive subjects. Despite this limitation, our findings underscore the prominence of lung pathology. Moreover, the prevalence of normal organs in cases of acute intoxication is a significant observation. We advocate for future research to provide more detailed insights to enhance our understanding of the multifaceted landscape of NPS-related deaths.

01 Dec 2024·ALCOHOL

Emerging pharmacological targets for alcohol use disorder

Review

Author: Crowley, Nicole A ; Brockway, Dakota F

Alcohol Use Disorder (AUD) remains a challenging condition with limited effective treatment options; however new technology in drug delivery and advancements in pharmacology have paved the way for discovery of novel therapeutic targets. This review explores emerging pharmacological targets that offer new options for the management of AUD, focusing on the potential of somatostatin (SST), vasoactive intestinal peptide (VIP), glucagon-like peptide-1 (GLP-1), nociceptin (NOP), and neuropeptide S (NPS). These targets have been selected based on recent advancements in preclinical and clinical research, which suggest their significant roles in modulating alcohol consumption and related behaviors. SST dampens cortical circuits, and targeting both the SST neurons and the SST peptide itself presents promise for treating AUD and various related comorbidities. VIP neurons are modulated by alcohol and targeting the VIP system presents an unexplored avenue for addressing alcohol exposure at various stages of development. GLP-1 interacts with the dopaminergic reward system and reduces alcohol intake. Nociceptin modulates mesolimbic circuitry and agonism and antagonism of nociceptin receptor offers a complex but promising approach to reducing alcohol consumption. NPS stands out for its anxiolytic-like effects, particularly relevant for the anxiety associated with AUD. This review aims to synthesize the current understanding of these targets, highlighting their potential in developing more effective and personalized AUD therapies, and underscores the importance of continued research in identifying and validating novel targets for treatment of AUD and comorbid conditions.

News (Medical) associated with Nelipepimut S

19 Dec 2023

·www.biospace.com

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis SECAUCUS, N.J., Dec. 19, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives. Two of these classes are rapidly accelerating America's overdose crisis: other illicit additives (xylazine) and fentanyl analogs (acetyl fentanyl). The new test panel is designed to help healthcare providers detect potential drug misuse in patients prescribed controlled medications, such as opioids and other substances, amid a proliferation of synthetic or "designer" drugs in the nation's drug supply. NPS are versions of established prescription and illicit drugs that are routinely chemically altered to enhance drug effects and evade tracking by law enforcement. As their chemical composition frequently evolves, conventional point-of-care and laboratory test methods may fail to detect NPS, increasing risks for individual patients and challenging efforts to understand their long-term health effects or prevalence in communities. The Quest panel uses definitive liquid chromatography with advanced tandem mass spectrometry-based testing to establish NPS misuse. Quest's team of toxicologists, medical experts and data analysts will periodically review and update the panel to include the most relevant and prevalent substances present in communities, as reflected by trends in the company's nationally representative Health Trends® dataset and the latest reports from public health, academic research and law enforcement organizations. Quest developed the panel to address the changing drug epidemic, as revealed by its nationally representatives Health Trends® report, "Drug Misuse in America 2023: The Growing Crisis of Novel Psychoactive Substances." Based on more than 3.6 million clinical laboratory drug tests performed by Quest Diagnostics in 2022, the report provides insights into the drug crisis and its shifts from misuse of prescription opioids and fentanyl to NPS. The report also includes analysis of 3,730 randomly selected "remnant" specimens tested using a pilot version of the new NPS test panel. Approximately 13.1% of remnant specimens tested were positive for at least one NPS. Of these, the animal tranquilizer xylazine was found in 8.1%, or nearly 1 in 12 specimens tested, making it the most prevalent single NPS. Yet, non-xylazine substances, including fentanyl analogs and designer benzodiazepines, were found in 5% of remnant specimens tested, or roughly 40% of all NPS-positive test results. These findings align with a recent report from the U.S. Centers for Disease Control and Prevention (CDC) highlighting the increasing connection between xylazine and opioid overdose deaths while also revealing growing misuse of other NPS. Additional key findings include: Xylazine positivity among fentanyl-positive specimens was most prevalent in the Southeast (~90%), Northeast (~80%) and Eastern (~60%) U.S. regions. Results in the Southwest (<30%) and on the West Coast (<20%) suggest xylazine has yet to fully penetrate these U.S. regions. One third (32.7%) of fentanyl positive specimens were also positive for xylazine and nearly all (97.7%) specimens positive for xylazine were also positive for fentanyl. Nearly 1 in 5 (19%) amphetamines-positive specimens showed fentanyl combining. Heroin use rapidly declined, as positivity overall fell from 1.1% in 2021 to 0.4% in 2022. The Health Trends analysis also found that specimens in areas with demographics linked to low income levels were nearly 7 times more likely to test positive for nonprescribed fentanyl than those linked to high-income communities. The researchers theorize that these differences are due to comparatively higher quality of care and generally greater access to resources in high-income communities. To access the full Health Trends report, click here. "Our Health Trends data demonstrates the importance of considering all possible NPS, not just xylazine, in clinical drug testing," said Harvey W. Kaufman, M.D., medical director and head of the Health Trends research program. "The faster public health and policy makers catch up with the growing problem of synthetic drugs, the greater the likelihood of curbing a dangerous and evolving drug epidemic before more lives are lost and more families and communities suffer irreversible harm." For more information, please visit . Quest Diagnostics Health Trends studies are performed on aggregate deidentified laboratory data in compliance with applicable privacy regulations and the company's strict privacy policies, and follow procedures approved by the WCG Institutional Review Board. The present study's strengths include its large data set, geographic scope, and validated testing by the highly reliable mass spectrometry method. Its limitations include geographic disparities and inability to validate or contextualize test results with medical records. The terms high- and low-income communities refer to certain geographies that have median income levels that fall in the highest and lowest quintile as determined by the U.S. Census Bureau. For the full study methodology, including strengths and weaknesses, please refer to the full report. About Quest Diagnostics Health Trends® Quest Diagnostics Health Trends® is a series of scientific reports that provide insights into health issues, based on patient laboratory data, to empower better patient care, population health management and public health policy. The reports are based on the HIPAA-compliant Quest Diagnostics database of more than 60 billion deidentified laboratory test datapoints. The Quest database is believed to be the largest of its kind in healthcare. Health Trends research has yielded novel insights into allergies and asthma, cancer, COVID-19, diabetes, heart disease, hepatitis, influenza, Lyme disease, prescription drug misuse and workplace wellness. Quest Diagnostics also produces the Drug Testing Index (DTI)™, a series of reports on national workplace drug positivity trends based on the company's employer workplace drug testing data. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. . Company Codes: NYSE:DGX

Clinical ResultClinical StudyDiagnostic Reagents

06 Jun 2023

·www.prnewswire.com

The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

Early data presented at ASCO annual meeting 2023 shows encouraging responses to treatment in a very difficult to treat patient population Dr. Anthony Kong (Guy's and St Thomas' Hospitals, London), Principal Investigator, presented data from ProcemISA, an ongoing clinical trial in anti-PD1 resistant advanced HPV16+ head and neck cancer OEGSTGEEST, The Netherlands, June 6, 2023 /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious diseases, presented the first clinical data of the combination of ISA101b (peltopepimut-S) and Regeneron's anti-PD-1 Libtayo® (cemiplimab) at the ASCO annual meeting in Chicago. Early data were presented regarding 26 patients with recurrent and/or metastatic Human Papilloma Virus type 16 (HPV16) positive oropharyngeal cancer (OPC, a form of head and neck cancer) who progressed on pembrolizumab or nivolumab, and were followed for at least 6 months. This population included patients that have never responded to prior anti-PD1 therapy. Patients were treated until disease progression, toxicity, treatment withdrawal or up to 24 months. Recruitment in this study is ongoing. Further information can be found on clinicaltrials.gov (NCT04398524). The combination of ISA101b and cemiplimab in these patients resulted in an overall response rate (ORR) of 15.4%, as per investigator assessment. Long term (≥6 months) disease stabilization was achieved in 26.9% of all patients. The combination of cemiplimab and ISA101b was generally well tolerated with a safety profile resembling that of anti-PD-1 monotherapy. There were two grade 3 adverse events related to ISA101b. Grade 4-5 events related to study treatment did not occur. Re-ignition of an anti-tumor effect of anti-PD-1 therapy after failure of checkpoint inhibition by the addition of a therapeutic vaccine is a unique feature. Dr. Anthony Kong, Principal Investigator and Medical Oncologist at King's College in London, said: "The initial results of this study are promising, given the high unmet medical need in this difficult-to-treat patient population." Leon Hooftman, Chief Medical Officer of ISA Pharmaceuticals, said: "The most impressive element of this data-set of anti-PD1 therapy-resistant head and neck cancer patients is the 6 months' Disease Control Rate' (DCR): it appears that the targeted therapeutic cancer vaccine ISA101b together with an anti-PD1 antibody can have a real stabilizing effect in a fair proportion of these sick patients." Head-and-neck cancer can be a severe and life-threatening disease. HPV16 is a major cause of head-and-neck cancer. Recurrent and metastatic HPV16 positive OPC is a form of head-and-neck cancer with a high unmet medical need. In September 2021 ISA101b was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent and metastatic HPV16 positive OPC. For more information, please visit us at isa-pharma.com or contact us at [email protected]. SOURCE ISA Pharmaceuticals B.V.

VaccineFast TrackClinical ResultImmunotherapyASCO

27 May 2021

·www.biospace.com

SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies- Patent term extends to at least 2036 -

NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance in a patent application covering the use of galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies for treatment of WT1-expressing cancers. “These new patent claims add to SELLAS’ growing intellectual property (IP) estate for GPS and continue to support the Company’s clinical studies of GPS in combination with checkpoint inhibitors in patients with advanced ovarian cancer and malignant pleural mesothelioma (MPM) who had exhausted their current standard therapy options,” said Angelos Stergiou, President and Chief Executive Officer, SELLAS. “This additional IP protection for GPS is a major milestone as we look to further advance our clinical pipeline. We look forward to providing further data from our study of GPS in combination with pembrolizumab in patients with 2nd or 3rd line relapsed/refractory metastatic ovarian cancer, as well as the study of GPS in combination with nivolumab in relapsed/refractory MPM later this quarter.” The allowed claims of the patent application cover the use of GPS in combination with any antibody checkpoint inhibitor that blocks or inhibits programmed cell death protein 1 (PD-1), such as nivolumab and pembrolizumab. The allowed claims of the patent application also cover treating, reducing the incidence of, or inducing an immune response against any WT1-expressing cancer, such as ovarian cancer and MPM. This patent application covering the use of GPS in combination with checkpoint inhibitors will be the first granted within a patent family filed in several countries and will have a term that extends to at least 2036. The patent application is expected to be granted on June 15, 2021, as U.S. Patent No. 11,033,613. About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care. For more information on SELLAS, please visit . Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development and intellectual property protection of GPS for various cancer indications, including ovarian cancer and MPM. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 23, 2021 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. For more information, please contact: Investor Contacts Valter Pinto / Allison Soss KCSA Strategic Communications Email: SELLAS@kcsa.com Phone: 914.907.2675 / 215.272.2707 Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications Email: SELLAS@kcsa.com Phone: 212.896.1241 / 212.896.1276

CollaborateAntibodyImmunotherapy

100 Deals associated with Nelipepimut S

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06226

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2-Low Breast Carcinoma	Phase 3	US	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	BG	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	CA	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	CZ	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	FR	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	DE	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	HU	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	IL	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	PL	Galena Biopharma, Inc.	01 Nov 2011
HER2-Low Breast Carcinoma	Phase 3	RO	Galena Biopharma, Inc.	01 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02297698 (HER3+, CTgov)	Phase 2	HER2 Positive Breast Cancer	100	GM-CSF+Trastuzumab+NeuVax vaccine (Trastuzumab + NeuVax)	tubwdefvqg(twtwwkpwfd) = fbjqovsafz omtlhwmaen (hmeihmziof, nqazhurzuu - ruxwjtyyvf) View more	-	12 Dec 2023
				GM-CSF+Trastuzumab (Trastuzumab + GM-CSF)	tubwdefvqg(twtwwkpwfd) = ecucebwtfq omtlhwmaen (hmeihmziof, ousgcrfyeh - zthacykodu) View more
NCT01570036 (phase IIb, CTgov)	Phase 2	HER2-negative breast cancer	275	Herceptin+GM-CSF+NeuVax vaccine (Herceptin + NeuVax Vaccine)	eegwvoowca(jcdymhsdyk) = rkhyqtcabr jvzaphnhmg (iefjqtohhd, oigfyhikyq - jaraltiehu) View more	-	02 Dec 2020
				Herceptin+GM-CSF (Herceptin + GM-CSF Only)	eegwvoowca(jcdymhsdyk) = vllnbxmttw jvzaphnhmg (iefjqtohhd, wkysphaolj - ofkghvcnzw) View more
NCT01479244 (Pubmed \| Clin Cancer Res) Manual	Phase 3	Breast Cancer	758	GM-CSF+Nelipepimut-S Vaccine	ffdkfyxjor(eevzygzfrj) = There was no significant between-arms difference in DFS events at interim analysis at median follow-up (16.8 months). sdaljjixcs (qdyqjuhhko ) View more	Negative	15 Jul 2019
				GM-CSF+placebo
NCT02297698 (ASCO2019)	Phase 2	Triple Negative Breast Cancer	275	Nelipepimut-S + Trastuzumab	yipijhgreg(yedxzolwwx) = upbjgkynvr autywibfas (egqsqdjqza, 0.026)	-	26 May 2019
				Trastuzumab	yipijhgreg(yedxzolwwx) = smzppwockg autywibfas (egqsqdjqza, 0.016)
NCT01570036 (phase IIb, ASCO_SITC2019)	Phase 2	HER2-Low Breast Carcinoma Adjuvant HLA-A2 \| HER2-LE \| TNBC	275	Nelipepimut-S + GM-CSF with trastuzumab	zhkhngduso(oosacmjsli) = The estimated DFS was favorable but did not reach significance in the VG compared with the CG jugimfwluh (lgbxklgkdz )	Positive	05 Mar 2019
				Trastuzumab with GM-CSF
NCT01570036 (ESMO2018) Manual	Phase 2	Triple Negative Breast Cancer HER2 Negative \| ER Negative \| PR Negative ... View more	275	trastuzumab+nelipeptimut-S (ITT)	tsoowxkocu(kqjqrofpno) = xtgeucglqv ieleodfrqw (gbwckmypwz )	Positive	22 Oct 2018
				trastuzumab (ITT)	tsoowxkocu(kqjqrofpno) = baajaudvhe ieleodfrqw (gbwckmypwz )
NCT00841399 (Pubmed \| Ann Oncol)	Phase 1/2	Breast Cancer Adjuvant	195	E75 (nelipepimut-S) vaccine (Vaccinated group (VG))	yidghiorqh(fxpktmvugw) = psiatwzprp hxsspqxvum (cxurfrhnej )	-	01 Sep 2014
				E75 (nelipepimut-S) vaccine (Control group (CG))	yidghiorqh(fxpktmvugw) = ybqcofayjv hxsspqxvum (cxurfrhnej )
NCT00841399 (ASCO2013)	Phase 1/2	Breast Cancer Adjuvant	195	Vaccine group (VG)	(bcbhpdrlau) = ilshrfnuhg loafokowif (oeafufmrzt )	-	20 May 2013
NCT00854789 \| NCT00841399 (study I-02, Pubmed \| Cancer)	Phase 1/2	Breast Cancer Adjuvant	-	E75 + GM-CSF vaccine booster at 6 months	qgrcbgerrh(ehyjijqtfb) = flyhmujutb fctanveddg (kunfhemjna ) View more	-	01 Feb 2011
				E75 + GM-CSF vaccine booster at >6 months	qgrcbgerrh(ehyjijqtfb) = ygouaavhlz fctanveddg (kunfhemjna ) View more
NCT00854789 \| NCT00841399 (Pubmed \| J Am Coll Surg)	Phase 1/2	Breast Cancer Adjuvant	-	E75 (HLA-A3+ breast cancer patients)	lwlzlrylpx(dabaakgslo) = fubofyehnh stenntvzgj (wphejptcbo )	-	01 Feb 2010
				E75 (HLA-A2- breast cancer patients)	lwlzlrylpx(dabaakgslo) = ptydiwsgjx stenntvzgj (wphejptcbo )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis